Format
Sort by

Send to

Choose Destination

Search results

Items: 20

1.

Characteristics and spread to the native population of HIV-1 non-B subtypes in two European countries with high migration rate.

Dauwe K, Mortier V, Schauvliege M, Van Den Heuvel A, Fransen K, Servais JY, Bercoff DP, Seguin-Devaux C, Verhofstede C.

BMC Infect Dis. 2015 Nov 16;15:524. doi: 10.1186/s12879-015-1217-0.

2.

Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants.

Van Beckhoven D, Florence E, Ruelle J, Deblonde J, Verhofstede C, Callens S, Vancutsem E, Lacor P, Demeester R, Goffard JC, Sasse A; BREACH Belgian Research on AIDS and HIV Consortium.

BMC Infect Dis. 2015 Nov 3;15:496. doi: 10.1186/s12879-015-1230-3.

3.

Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs.

Malatinkova E, De Spiegelaere W, Bonczkowski P, Kiselinova M, Vervisch K, Trypsteen W, Johnson M, Verhofstede C, de Looze D, Murray C, Kinloch-de Loes S, Vandekerckhove L.

Elife. 2015 Oct 6;4:e09115. doi: 10.7554/eLife.09115.

4.

Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.

De Spiegelaere W, Philippé J, Vervisch K, Verhofstede C, Malatinkova E, Kiselinova M, Trypsteen W, Bonczkowski P, Vogelaers D, Callens S, Ruelle J, Kabeya K, De Wit S, Van Acker P, Van Sandt V, Emonds MP, Coucke P, Sermijn E, Vandekerckhove L.

PLoS One. 2015 Apr 15;10(4):e0123525. doi: 10.1371/journal.pone.0123525. eCollection 2015.

5.

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.

Kiselinova M, Anna M, Malatinkova E, Vervish K, Beloukas A, Messiaen P, Bonczkowski P, Trypsteen W, Callens S, Verhofstede C, De Spiegelaere W, Vandekerckhove L.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19823. doi: 10.7448/IAS.17.4.19823. eCollection 2014.

6.

Factors associated with the continuum of care of HIV-infected patients in Belgium.

Van Beckhoven D, Lacor P, Moutschen M, Piérard D, Sasse A, Vaira D, Van den Wijngaert S, Vandercam B, Van Ranst M, Van Wijngaerden E, Vandekerckhove L, Verhofstede C, Verbrugge R, Demeester R, De Wit S, Florence E, Fransen K, Delforge ML, Goffard JC, Goubau P.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19534. doi: 10.7448/IAS.17.4.19534. eCollection 2014.

7.

Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Zidovec Lepej S, Lunar MM, Mukabayire O, Schuurman R, Tomazic J, Van Laethem K, Vandekerckhove L, Wensing AM; International Viral Load Assay Collaboration.

J Clin Microbiol. 2014 Feb;52(2):517-23. doi: 10.1128/JCM.02461-13. Epub 2013 Dec 4.

8.

Socio-economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living with HIV in Belgium: a pilot study.

Degroote S, Vogelaers DP, Vermeir P, Mariman A, De Rick A, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Verhofstede C, Vandijck DM.

J Int AIDS Soc. 2013 Dec 12;16:18643. doi: 10.7448/IAS.16.1.18643.

9.

Frequency and predictors of HIV-1 co-receptor switch in treatment naive patients.

Mortier V, Dauwe K, Vancoillie L, Staelens D, Van Wanzeele F, Vogelaers D, Vandekerckhove L, Chalmet K, Verhofstede C.

PLoS One. 2013 Nov 7;8(11):e80259. doi: 10.1371/journal.pone.0080259. eCollection 2013.

10.

HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].

Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D, da Silva ES, Verhofstede C, Lie Y, Seguin-Devaux C, Schmit JC, Bercoff DP.

PLoS One. 2013 May 8;8(5):e60566. doi: 10.1371/journal.pone.0060566. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/7c0b830d-e75d-4128-ab54-7d5ecfd99d19.

11.

Characterization of LEDGF/p75 genetic variants and association with HIV-1 disease progression.

Messiaen P, De Spiegelaere W, Alcami J, Vervisch K, Van Acker P, Verhasselt B, Meuwissen P, Calonge E, Gonzalez N, Gutierrez-Rodero F, Rodriguez-Martín C, Sermijn E, Poppe B, Vogelaers D, Verhofstede C, Vandekerckhove L.

PLoS One. 2012;7(11):e50204. doi: 10.1371/journal.pone.0050204. Epub 2012 Nov 30.

12.

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ.

J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31.

13.

Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections.

Chalmet K, Staelens D, Blot S, Dinakis S, Pelgrom J, Plum J, Vogelaers D, Vandekerckhove L, Verhofstede C.

BMC Infect Dis. 2010 Sep 7;10:262. doi: 10.1186/1471-2334-10-262.

14.

HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.

Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ.

AIDS Res Ther. 2010 Feb 15;7:4. doi: 10.1186/1742-6405-7-4.

15.

Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya.

Steegen K, Luchters S, Dauwe K, Reynaerts J, Mandaliya K, Jaoko W, Plum J, Temmerman M, Verhofstede C.

AIDS Res Ther. 2009 Jun 16;6:12. doi: 10.1186/1742-6405-6-12.

16.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, Piérard D, Verhofstede C, Van Laethem K, Delforge ML, Vaira D, Schmit JC, Goubau P.

BMC Infect Dis. 2008 Feb 27;8:21. doi: 10.1186/1471-2334-8-21.

17.

Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots.

Steegen K, Luchters S, Demecheleer E, Dauwe K, Mandaliya K, Jaoko W, Plum J, Temmerman M, Verhofstede C.

J Clin Microbiol. 2007 Oct;45(10):3342-51. Epub 2007 Aug 1.

18.

Diversity of the human immunodeficiency virus type 1 (HIV-1) env sequence after vertical transmission in mother-child pairs infected with HIV-1 subtype A.

Verhofstede C, Demecheleer E, De Cabooter N, Gaillard P, Mwanyumba F, Claeys P, Chohan V, Mandaliya K, Temmerman M, Plum J.

J Virol. 2003 Mar;77(5):3050-7.

19.

Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.

Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF, Rossau R.

Antimicrob Agents Chemother. 1997 Feb;41(2):284-91.

20.
Items per page

Supplemental Content

Loading ...
Write to the Help Desk